Skip to main content
. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888

graphic file with name tayd015623.f13_default.jpg

Fig 13 Risk ratios for discontinuation because of adverse effects for agomelatine v placebo. Weights are from random effects analysis